Brendan Smith - 14 Oct 2021 Form 4 Insider Report for CRISPR Therapeutics AG (CRSP)

Role
Chief Financial Officer
Signature
/s/ Michael Esposito, attorney-in-fact
Issuer symbol
CRSP
Transactions as of
14 Oct 2021
Net transactions value
$0
Form type
4
Filing time
18 Oct 2021, 20:00:39 UTC
Previous filing
14 Sep 2021
Next filing
22 Feb 2022
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CRSP Restricted Stock Units Award $0 +15,000 $0.000000 15,000 14 Oct 2021 Common Shares 15,000 Direct F1, F2
transaction CRSP Stock Option (Right to Buy) Award $0 +90,000 $0.000000 90,000 14 Oct 2021 Common Shares 90,000 $98.70 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares.
F2 This restricted stock unit award was granted on October 14, 2021 with respect to 15,000 Common Shares, with (i) one quarter of the shares vesting on October 14, 2022, (ii) one quarter of the shares vesting on October 14, 2023, (iii) one quarter of the shares vesting on October 14, 2024, and (iv) one quarter of the shares vesting on October 14, 2025.
F3 This option was granted on October 14, 2021 with respect to 90,000 Common Shares, with 25% of the shares vesting on October 14, 2022 and the remaining shares vesting on each monthly anniversary thereafter for a period of 36 months.